Search Results - joseph+steiner

1 Results Sort By:
D3-Selective Dopamine Agonist Platform: Eliminating D2-Mediated Side Effects in Parkinson’s and Movement Disorders
Every major dopaminergic therapy on the market today shares the same fundamental limitation: it cannot distinguish between two closely related receptor subtypes (D2 and D3). This technology changes that. We have discovered and optimized a novel small molecule, ML417, that selectively activates the D3 dopamine receptor while leaving its close cousin,...
Published: 8/4/2026   |   Updated: 8/4/2026   |   Inventor(s): David Sibley, Juan Marugan, Benjamin Free, Amy Moritz, Jeffrey Aube, Joseph Steiner, Kevin Frankowski, Marc Ferrer-Alegre, Noel Southall, Xin Xu, Warren Weiner
Keywords(s):  
Category(s): TherapeuticArea > Neurology, Application > Therapeutics